Z-100

Cervical Cancer Drugs: Industry Trends and Opportunity Forecast, 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022
Oncology, AIDS, Health, Consumer, Women, Pharmaceutical, Biotechnology, Woman, Z-100, Risk, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Inflammation, Novartis, Cervical cancer, Bristol Myers Squibb, Diagnosis, Bowen University, Growth, Cancer, Geography, College of Arts and Sciences, Prevalence, Allergan, Eli Lilly and Company, GlaxoSmithKline, Degenerative disease, Pessary, National, COVID-19, Company, Gel, Acquisition, CD4, ICH, Awareness, Human, CAGR, Forecasting, Alnylam Pharmaceuticals, Tablet, HIV, Vagina, Celgene, International Council, Harmonization, Immune system, Disease, Birth control, Pharmaceutical industry, Oil, Retail, Pfizer, Cidofovir

The "Cervical Cancer Drugs Global Market Report 2022, Cancer Type, Drug Type, Distribution Channel" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Cancer Drugs Global Market Report 2022, Cancer Type, Drug Type, Distribution Channel" report has been added to ResearchAndMarkets.com's offering.
  • North America is the largest region in the cervical cancer drugs market in 2021.
  • The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market.
  • The lack of awareness and other misconceptions about cervical cancers hinder the growth of the cervical cancer drugs market.

Global Cervical Cancer Drugs Market (2021 to 2030) - Featuring Hetero, GlaxoSmithKline and Allergan Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, December 20, 2021
General Health, Pharmaceutical, Health, Oncology, Benchmark, Oncology Drug Advisory Committee, Oncology, Cervical cancer, FDA, Z-100, CD4, Awareness, Diagnosis, Gel, ICH, Division, Harmonization, Create, Human, Bowen University, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, National, Safety, Prevalence, Disease, Gynecologic cancer disparities in the United States, Risk, Woman, Tablet, College of Arts and Sciences, Coronavirus, Food, Immune system, HIV, Vagina, International Council, Growth, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pessary, Marketing, Birth control, Cidofovir

The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market.

Key Points: 
  • The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market.
  • The lack of awareness and other misconceptions about cervical cancers hinder the growth of the cervical cancer drugs market.
  • For instance, companies introduced vaginal gels such as Cidofovir gel and 851B Gel into the market to treat cervical cancer.
  • In addition to the above mentioned gels, drugs such as ISA101, AGEN2034 and Z-100 are in pipeline and promise growth to the cervical cancer drugs market.